India has introduced a product patent regime for pharmaceutical inventions and those patent applications filed through the WTO/mail box are now being examined. There are approximately 6,000 of these patent applications in the pipeline, which will be examined under the amended Patents Act (which no longer contains the controversial section that provided only limited term process patent protection for food and drugs). The amended law places a number of interesting limitations on pharmaceutical product patents originating through the WTO/mail box. One such limitation is that the rights of a patentee (of a pharmaceutical product invention) only begin from the date that the patent is granted. This provision considerably restricts the patentee's rights to institute an infringement action from the date that they file the application, which is the date from which the term of the patent is calculated in all other cases.